Ibandronic acid


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Hypercalcaemia of malignancy
Adult: 2-4 mg as a single infusion over 2 hr. Max: 6 mg.

Intravenous
Postmenopausal osteoporosis
Adult: 3 mg by inj over 15-30 seconds once every 3 mth. Missed dose: Give inj as soon as possible; then re-schedule next inj 3 mth from this inj; should not be given more frequently than once every 3 mth.

Intravenous
Prophylaxis of skeletal events in patients with bone metastases, Prophylaxis of skeletal events in patients with breast cancer
Adult: 6 mg by infusion over at least 15 min 3-4 wkly.

Oral
Prophylaxis of skeletal events in patients with bone metastases, Prophylaxis of skeletal events in patients with breast cancer
Adult: 50 mg daily

Oral
Postmenopausal osteoporosis, Prophylaxis of postmenopausal osteoporosis
Adult: 150 mg once mthly on the same date each mth, alternatively, 2.5 mg daily. Missed once-mthly dose: If next scheduled dose is >7 days away: Take dose the next morning and return to original schedule; if next dose is <7 days away: Wait until the next scheduled dose; 2 tabs must not be taken w/in the same wk.
Renal Impairment
Oral:
Prophylaxis of skeletal events in patients with breast cancer and bone metastases:
CrCl (mL/min) Dosage
<30 50 mg once wkly.
30-49 50 mg every other day.
Postmenopausal osteoporosis; Prophylaxis of postmenopausal osteoporosis:
CrCl (mL/min) Dosage
<30 Not recommended.
Intravenous:
Hypercalcaemia of malignancy; Postmenopausal osteoporosis:
CrCl (mL/min) Dosage
<30 Not recommended.
Prophylaxis of skeletal events in patients with breast cancer and bone metastases:
CrCl (mL/min) Dosage
<30 2 mg in 500 mL soln infused over 1 hr 3-4 wkly.
30-49 4 mg in 500 mL soln infused over 1 hr 3-4 wkly.
Cách dùng
Should be taken on an empty stomach. Must be taken at least 1 hr before the 1st food, drink or medication of the day. Take w/ a full glass of only plain water upon arising for the day & remain in sitting/upright position for at least 1 hr. Do not lie down, eat/drink anything except plain water or take other oral medicines for at least 1 hr. Swallow whole, do not chew/crush/suck.
Hướng dẫn pha thuốc
Prevention of skeletal events: Add contents of vial to 100 mL of NaCl 0.9% or dextrose 5%.
Treatment of hypercalcaemia of malignancy: Add contents of vial to 500 mL of NaCl 0.9% or dextrose 5%.
Tương kỵ
Ca-containing soln.
Chống chỉ định
Hypocalcaemia; oesophageal abnormalities which may delay emptying (e.g. stricture or achalasia), inability to stand or sit upright for at least 60 min (oral).
Thận trọng
Patient w/ disturbances of bone and mineral metabolism. Severe renal impairment (CrCl <30 mL/min). Pregnancy and lactation.
Phản ứng phụ
Flu-like symptoms (e.g. myalgia, arthralgia, fever, chills, fatigue, nausea, loss of appetite, bone pain), atypical fractures, osteonecrosis of the jaw, ocular inflammation, acute renal failure, hypocalcaemia, musculoskeletal pain. Rarely, anaemia, bronchospasm, taste disturbance, paraesthesia, uraemia; transient fever (IV); abdominal pain, dyspepsia, severe oesophageal reactions (oral).)
Potentially Fatal: Anaphylactic reaction/shock.
IV/Parenteral/PO: C
Thông tin tư vấn bệnh nhân
Ensure adequate Ca and vit D intake.
MonitoringParameters
Monitor serum Ca, Mg and phosphate; serum creatinine prior to each IV dose; bone mineral density (osteoporosis).
Quá liều
Symptoms: IV: Hypocalcaemia;, hypophosphatemia and hypomagnesaemia. Oral: Upper GI effects (e.g. stomach upset, oesophagitis, dyspepsia, gastritis, ulcer). Management: IV: Admin IV Ca gluconate, K or Na phosphate, and Mg sulfate when appropriate. Oral: May give milk or antacid to bind the drug.
Tương tác
Decreased absorption w/ Ca supplements, antacids and other multivalent cation-containing oral drugs. Increased incidence of GI irritation w/ aspirin or NSAIDs.
Food Interaction
Food may reduce absorption.
Lab Interference
May interfere w/ diagnostic imaging agents (e.g. technetium-99m-diphosphonate) in bone scans.
Tác dụng
Description: Ibandronic acid inhibits osteoclast activity w/o directly affecting bone formation resulting to increased bone mass and a decreased incidence of fractures through reduction of elevated bone turnover.
Pharmacokinetics:
Absorption: Poorly absorbed from the GI tract. Decreased absorption w/ food. Bioavailability: <1%. Time to peak plasma concentration: 0.5-2 hr (oral).
Distribution: Plasma protein binding: Approx 87%.
Metabolism: Not metabolised.
Excretion: Via urine (approx 50-60% of absorbed dose) as unchanged drug; faeces (unabsorbed drug). Terminal half-life: Approx 5-25 hr (IV); 37-157 hr (oral).
Đặc tính

Chemical Structure Image
Ibandronic acid

Source: National Center for Biotechnology Information. PubChem Database. Ibandronic Acid, CID=60852, https://pubchem.ncbi.nlm.nih.gov/compound/Ibandronic-Acid (accessed on Jan. 21, 2020)

Bảo quản
Store between 15-30°C.
Phân loại ATC
M05BA06 - ibandronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
References
Anon. Ibandronate . Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/09/2015.

Buckingham R (ed). Ibandronate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/09/2015.

Ibandronate Sodium Injection, Solution (Mylan Institutional LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/09/2015.

Ibandronate Sodium Tablet, Film-Coated (Apotex Corp). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/09/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ibandronic acid từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Bonviva
  • Drofen
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in